Biopharma M&A slowed to a crawl in the first half of 2025, amid regulatory, pricing, and geopolitical uncertainties.

In an interview with Michael Gibney, Managing Partner Michael Abrams discussed how multiple shocks in 2025 put a damper on potential deals and reshaped how pharma leaders are making long-term decisions.

“Every day was another headline that was a shocker,” Abrams said, leading to companies focusing on “reorganizing and re-budgeting for a future that seemed to change every other day.”

But as upcoming patent cliffs loom, there’s added pressure for Big Pharma to make more proactive moves.

Read more on PharmaVoice.com.